Literature DB >> 23782936

Pursuing the curative blueprint for early myeloma.

Mark Roschewski1, Neha Korde, S Peter Wu, Ola Landgren.   

Abstract

Treatment philosophies in multiple myeloma (MM) debate the relative merits of achieving the deepest possible remissions ("curative" doctrine) vs sequential delivery of antimyeloma agents ("control" doctrine). In this paper, we highlight the relevant strengths of each doctrine in the context of modern patient selection strategies, fresh biological insights on MM pathogenesis, agents with improved safety profiles, and emerging molecular and imaging tools. Paramount fundamental questions remain unanswered that require an intense research focus as we pursue a cure for this devastating disease.

Entities:  

Mesh：

Year:  2013        PMID： 23782936      PMCID： PMC3724188          DOI： 10.1182/blood-2013-01-481291

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  27 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Authors:  Andrzej J Jakubowiak; Dominik Dytfeld; Kent A Griffith; Daniel Lebovic; David H Vesole; Sundar Jagannath; Ammar Al-Zoubi; Tara Anderson; Brian Nordgren; Kristen Detweiler-Short; Keith Stockerl-Goldstein; Asra Ahmed; Terri Jobkar; Diane E Durecki; Kathryn McDonnell; Melissa Mietzel; Daniel Couriel; Mark Kaminski; Ravi Vij
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

3.  Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.

Authors:  Jens Hillengass; Sofia Ayyaz; Kerstin Kilk; Marc-André Weber; Thomas Hielscher; Rajiv Shah; Dirk Hose; Stefan Delorme; Hartmut Goldschmidt; Kai Neben
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

4.  Approach to the treatment of multiple myeloma: a clash of philosophies.

Authors:  S Vincent Rajkumar; Gösta Gahrton; P Leif Bergsagel
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

5.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

6.  The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.

Authors:  Lucía López-Corral; Norma C Gutiérrez; Maria Belén Vidriales; Maria Victoria Mateos; Ana Rasillo; Ramón García-Sanz; Bruno Paiva; Jesús F San Miguel
Journal:  Clin Cancer Res       Date:  2011-02-16       Impact factor: 12.531

7.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 8.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

Review 9.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

10.  Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Lorenzo Melchor; Sanna Hulkki; Nicola E Potter; David C Johnson; Kerry Fenwick; Iwanka Kozarewa; David Gonzalez; Christopher J Lord; Alan Ashworth; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2012-05-09       Impact factor: 22.113
View more
  6 in total

1.  Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.

Authors:  Elisabet E Manasanch; Dalia A Salem; Constance M Yuan; Nishant Tageja; Manisha Bhutani; Mary Kwok; Dickran Kazandjian; George Carter; Seth M Steinberg; Diamond Zuchlinski; Marcia Mulquin; Katherine Calvo; Irina Maric; Mark Roschewski; Neha Korde; Raul Braylan; Ola Landgren; Maryalice Stetler-Stevenson
Journal:  Leuk Lymphoma       Date:  2014-10-30

2.  Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.

Authors:  Elisabet E Manasanch; Neha Korde; Sham Mailankody; Nishant Tageja; Manisha Bhutani; Mark Roschewski; Ola Landgren
Journal:  Haematologica       Date:  2014-12       Impact factor: 9.941

3.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Authors:  Neha Korde; Mark Roschewski; Adriana Zingone; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Nishant Tageja; Dickran Kazandjian; Sham Mailankody; Peter Wu; Candis Morrison; Rene Costello; Yong Zhang; Debra Burton; Marcia Mulquin; Diamond Zuchlinski; Liz Lamping; Ashley Carpenter; Yvonne Wall; George Carter; Schuyler C Cunningham; Verena Gounden; Tristan M Sissung; Cody Peer; Irina Maric; Katherine R Calvo; Raul Braylan; Constance Yuan; Maryalice Stetler-Stevenson; Diane C Arthur; Katherine A Kong; Li Weng; Malek Faham; Liza Lindenberg; Karen Kurdziel; Peter Choyke; Seth M Steinberg; William Figg; Ola Landgren
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

Review 4.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

5.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

6.  Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies.

Authors:  Praful Ravi; Shaji K Kumar; James R Cerhan; Matthew J Maurer; David Dingli; Stephen M Ansell; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2018-02-28       Impact factor: 11.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.